Theravance Biopharma, Inc. (TBPH)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Development and Commercialization of Human Therapeutics	107.46M	64.38M	57.42M	51.35M	55.31M
Development and Commercialization of Human Therapeutics Growth	66.92%	12.12%	11.84%	-7.17%	-23.03%
Total	107.46M	64.38M	57.42M	51.35M	55.31M
Total Growth	66.92%	12.12%	11.84%	-7.17%	-23.03%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
United States	74.96M	64.38M	57.20M	51.12M	55.27M
United States Growth	16.44%	12.55%	11.89%	-7.51%	-21.40%
Europe	32.50M	-	223.00K	222.00K	38.00K
Europe Growth	-	-	0.45%	484.21%	-97.53%
Total	107.46M	64.38M	57.42M	51.35M	55.31M
Total Growth	66.92%	12.12%	11.84%	-7.17%	-23.03%

Data Source: S&P Global Market Intelligence Last updated: May 7, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 25, 2026

Data Sources Report a data error